Hattan Fatani

• Establish the first Sandoz OTC Business model for Sandoz.
• Build Sandoz muscles to compete in private sector to penetrate both hospitals and pharmacy chains segments.
• Assemble a group of talented salespersons and marketers to form the core team for retail and OTC
• Set organizational strategies and operational plans
• Prepare Integrated Product mix to launch the OTC project.
• Manage the BU P&L and deliver financial targets
• Activate partnership projects with pharmacy chains
• Support GLS claustral growth and efficient regional environment as an active LT member

• Double digit growth in a 3rd year on a row in 2020 - 2022
• Kick off hyper growth annual plan for Sandoz to unleash potential of all Sandoz portfolio by building new functions and grow the organization.
• Lead a multifunctional team to reserve the 1st rank in Generic and Biosimilars in Saudi
• Build a high performing team with empowered individuals merging a currently high caliber team with newly attracted talents.
• Set a solid and sustainable standard work process with local channel partner.
• Create the right strategy and efficient tactics for Biosimilar portfolio.
• Participate in building several franchises and grow Sandoz following the success on Immunology franchise

(Kerr Consumables & Kavo Instruments/Dental Units)

• Set strategies for consumables portfolio to reach targeted vision.
• Spread brand awareness through transformative marketing activities.
• Lead Africa growth plan in specific focus countries
• Set annual marketing plans with efficient strategies and tactical plans
• Develop market visibility tools, part of EMEA Market intelligence projects
• Expand sales channels
• Handle Spin off Assignment and achieve a successful kick off of Envisat Dental
• Run marketing activities all over MEA
• Manage Kavo dental technology as an extended role since in 2017 and full responsibility in 2019
• Develop Kavo instruments as extended responsibility in 2018 and full responsibility in 2019
• Growth in Kerr strategic portfolio ( 3 years CAGR 65%)
• Employed fact-based decision-making, rooted in category, customer and shopper insights.

(Kerr Consumables)

• Manger regional trade operational in Middle east countries to develop consumables business
• Support building annual marketing plans and local activities through local partners
• Triple folds growth in Nigeria and gain leadership position in dental consumables
• Expand Kerr business by penetrating potential countries and handle a successful access plans

(GSK Oncology - Novartis Oncology, Hematology Portfolio)

• Launch Arzerra in Chronic Lymphocytic leukemia (1st country in MENA region)
• Grow Revoalde revenues to more than 200% by leading marketing projects
• Initiating e marketing /multichannel marketing projects
• Grant regional and global support for Saudi hematology strategies/tactics
• MEA marketing champion for hematology
• Quality assurance champion for whole specialty unit
• Active participation in integration process after global acquisition with Novartis

(Novartis Oncology, Hematology Line, Jakavi)

• Launch Jakavi as new standard of care for MF patients
• Drive strong local, regional and global support to solid operate pre-launch activities
• Winner of global award (Saudi Jakavi team) for prelaunch proposed projects

Novartis Oncology

• Manage diversified KAM team (3 Regional KAMs)
• Implement long term partnership plans with key accounts in Saudi (e.g. NG & MOH)
• Winning main national tenders SGH, NG (3 years tender) and MODA (3 years tender)
• Manage local tenders KAMC-OC, KFMC and KFSH-Dammam
• Achieve overall growth in main tenders by 80% in 2012
• Achieve organization target in 2011 and 2012
• Global strategic projects e.g. Novartis ME champ for E-detailing project and APT
• Grow mature products (Glivec)
• Certified as Novartis assessor (only 2 in national level)
• Responsible for commercial excellence activities in 2012

➢ Formulary inclusion for strategic products (Afinitor, Tasigna in KFSH and NG).

➢ Responsible for Novartis Oncology portfolio (Jakavi, Glivec, Tasigna, Exjade, Afinitor, Sandostatin Lar, Zometa and Femara)

(Specialty, Western Region - Saudi)

• Drive formulary inclusions in all governmental sectors within western and southern region
• Monitor Performance within hospitals and generate opportunities
• Aclasta inclusion in SGH

(Novartis Oncology hematology franchise – Exjade)

• Responsible for MOH and Private hospitals
• 2nd Best Achiever, National in 2010

(Overall Achievement of vs Target105%)

(Novartis Gen Med Private/ institution –CVM)

• 2nd Best achiever in WZ cardiovascular line private sector 2008 (107%)
• Participation in mega launches (Rasilez, Exforge, Diovan new forms and Galvus)
• Over achievement of allocated targets in 2009 (Oncology ended by 112%)

(In patients pharmacy, Pediatric Hospital)

(Vaygon ,Antimicrobial catheters)

• Sales and poromotion in central region